Excreted Unchanged %
Hepatic
Half-Life (Normalesrd) Hours
24-72/Unchanged
Plasma Protein Binding %
94.5
Volume Of Distribution L/Kg
12-42
Dose For Normal Renal Function
20 mg q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994; 26: 201-14. [PMID: 8194283] / Gram L. Fluoxetine. N Engl J Med. 1994; 331: 1354-61. [PMID: 7935707] / Goodnick PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet. 1994; 27: 307-30. [PMID: 7834966] / Sussman N, Stahl S. Update in the pharmacotherapy of depression. Am J Med. 1996; 101: 26S-36S. [PMID: 9012608]
Toxicity Notes
T1/2 of active metabolite is 7-9 days.